AMD Beyond Complement and Serine Protease Pathways
About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
April 01, 2007 - March 31, 2010
Grant ID
M2007084
Goals
This study will characterize two new genetic risk factors related to wet and dry AMD
Summary
Age-related macular degeneration (AMD) has a complex etiology and is broadly classified as either dry or wet. The dry form is more common, accounting for approximately 90% of patients, and does not typically result in blindness. About 10% of patients have the wet form, in which central vision will be destroyed. We have identified two major genetic factors predisposing some individuals to the more aggressive wet form of AMD and others to the slowly progressing dry type. Together with the new risk factors we will discover, it will be possible to detect who is at increased risk and allow those affected to take preventive measures.
Related Grants
Macular Degeneration Research
How Retinal Cells Drive Inflammation in Age Related Macular Degeneration
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Sarah Palko, PhD
Current Organization
Trinity College Dublin
How Retinal Cells Drive Inflammation in Age Related Macular Degeneration
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Sarah Palko, PhD
Current Organization
Trinity College Dublin
Macular Degeneration Research
Uncovering the Hidden Link Between Liver Health and Macular Degeneration
Active Dates
July 01, 2026 - June 30, 2029
Principal Investigator
Sunghee Park, PhD
Current Organization
Purdue University
Uncovering the Hidden Link Between Liver Health and Macular Degeneration
Active Dates
July 01, 2026 - June 30, 2029
Principal Investigator
Sunghee Park, PhD
Current Organization
Purdue University
Macular Degeneration Research
Advancing AMD Diagnosis with Novel Spectroscopic Tools
Active Dates
July 01, 2026 - June 30, 2029
Principal Investigator
David Veysset, PhD
Current Organization
Massachusetts General Hospital
Advancing AMD Diagnosis with Novel Spectroscopic Tools
Active Dates
July 01, 2026 - June 30, 2029
Principal Investigator
David Veysset, PhD
Current Organization
Massachusetts General Hospital